In the News: When Will We See the Full Benefits of Biosimilars?

Monday, January 29, 2018

Since 2015, the healthcare industry has been tracking the progress and awaiting the wide-scale availability of biosimilars, a potentially more affordable alternative to biologic products. But the slow proliferation of these products continues to be the difficulty in getting them to market and navigating the many twists and turns of the regulatory and reimbursement process. These issues were discussed in the recent Drug Store News article, “Biosimilars poised to bring savings — if they get to launch”.

The DSN article notes that, despite projections of billions of dollars in potential savings from biosimilar drugs as biologics lose patent protections, the hurdles these drugs have to overcome to make it to market delay release, eat into potential profits, and keep patients from having access to treatments that may be priced 10-15% lower than their reference drugs.

Largely the obstacles these products face are legal, as biosimilars have to prove they are not violating the intellectual property rights of their reference products in order to secure approval. Litigation from the manufacturer of the reference product has impacted FDA approval and timing of release in several cases so far.

Other issues that complicate the approval of biosimilars include:

  • Naming conventions
  • Interchangeability of biosimilars with their reference products
  • Inconsistent payment rates for reimbursement

The article quoted a RAND report: “We must put the patient at the center of the FDA’s guidance for naming and interchangeability to reduce confusion and unreasonable requirements that ultimately impact patient access.”

Read the full Drug Store News article.

You may also like:

Blog Post

There have been millions invested in healthcare technology over the past 10 years focused primarily on improving the administrative efficiency of our healthcare system and providing greater access and coverage. Today, as the he...

View Blog Post
Blog Post

The appropriateness and safety of pain relievers are an issue of great concern for all prescribers, including dental professionals. A study published in 2017 sought to determine current evidence on postoperative strategies to r...

View Blog Post
Blog Post

The Centers for Disease Control and Prevention (CDC) recently recognized its annual World Tuberculosis (TB) Day on March 24. It is a time to reinforce the global healthcare community’s commitment to ending the spread of the b...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up